CJC-1295 and Ipamorelin: What the Science Actually Says

CJC-1295 and ipamorelin are frequently paired in discussions about growth hormone support. Each works differently, and the research behind them differs too. This guide explains what they are, what studies show, and the regulatory context you should keep in mind.

How CJC-1295 and ipamorelin work

CJC-1295 is a long-acting analog of growth hormone releasing hormone, which prompts the pituitary gland to release growth hormone. Ipamorelin acts on a different receptor, the ghrelin receptor, to encourage growth hormone release with high selectivity. People often discuss them together because they engage two complementary pathways.

What the studies show

On CJC-1295, a randomized, placebo-controlled trial in healthy adults found that subcutaneous injections produced dose-dependent increases in growth hormone and IGF-1, and were generally well tolerated in that study [1]. This is one of the more useful pieces of human data in this area.

On ipamorelin, the foundational 1998 research characterized it as the first selective growth hormone secretagogue, releasing growth hormone without meaningfully raising cortisol or prolactin. That early work was preclinical, and human data for ipamorelin remains limited [2].

Regulatory status and honest context

Neither CJC-1295 nor ipamorelin is approved by the U.S. Food and Drug Administration for the uses discussed here, and the human evidence base is smaller than the enthusiasm around these peptides suggests. Both also fall within categories prohibited by the World Anti-Doping Agency, so they are not permitted for athletes in tested competition.

This is why supervision matters. A licensed provider can separate what the research supports from what is marketing, and help you weigh the picture honestly.

The LIVV approach to CJC-1295 and ipamorelin

A consultation comes first, so a clinician can review your goals and health history before anything else. That lets you weigh what the research does and does not support. It also keeps the conversation grounded and personal.

Ready for a personalized answer? You can book a naturopathic consultation with LIVV.

Related LIVV peptides and stacks

• LIVV’s CJC-1295 and Ipamorelin product page to review with a licensed provider.
• LIVV’s hormone optimization peptides for related options within the same category.

Related reading: LIVV’s comparison of Sermorelin versus CJC and Ipamorelin.

Frequently asked questions

Are CJC-1295 and ipamorelin the same thing?

No. CJC-1295 is a growth hormone releasing hormone analog, while ipamorelin acts on the ghrelin receptor. They engage different pathways.

Is there human evidence for these peptides?

CJC-1295 has a human trial showing raised growth hormone and IGF-1 [1], while ipamorelin’s foundational data is largely preclinical [2].

Are these peptides approved by the FDA?

No. Neither is approved by the U.S. Food and Drug Administration for these uses, and both are prohibited in tested sport by the World Anti-Doping Agency.

References

1. Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PMID: 16352683 (view on PubMed)
2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID: 9849822 (view on PubMed)

Medical disclaimer
This article is for general education and is not a substitute for personalized medical advice, diagnosis, or treatment. Talk with a qualified healthcare provider before starting any new therapy. Individual results vary.

Regulatory note
CJC-1295 and ipamorelin is not approved by the U.S. Food and Drug Administration for the uses discussed here, and much of the available research comes from laboratory and animal studies. Any use should be under the supervision of a licensed provider.
Athletes should note that these compounds fall within categories prohibited by the World Anti-Doping Agency and are not permitted in tested competition.